Yun Jee Kang

US Patent:

7939083, May 10, 2011

Filed:

Oct 17, 2007

Appl. No.:

12/312016

Inventors:

Antu K. Dey - Auburndale MA, US
John P. Moore - New York NY, US
William C. Olson - Yorktown Heights NY, US
Yun (Kenneth) Kang - Livingston NJ, US
Michael Franti - Cambridge MA, US

Assignee:

Progenics Pharmaceuticals Inc. - Tarrytown NY

International Classification:

A61K 39/21
A61K 39/12

US Classification:

4242081, 4241881, 4241991

Abstract:

This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof. Also provided are antibodies generated against the modified polypeptides and trimeric complexes, and methods of using the modified polypeptides, compositions and trimeric complexes.

US Patent:

20110250220, Oct 13, 2011

Filed:

May 4, 2011

Appl. No.:

13/100941

Inventors:

Antu K. Dey - Auburndale MA, US
John P. Moore - New York NY, US
William C. Olson - Yorktown Heights NY, US
Yun (Kenneth) Kang - Livingston NJ, US
Michael Franti - Cambridge MA, US

International Classification:

A61K 39/21
A61P 31/18
A61P 37/04
C07K 14/16
C12P 21/00

US Classification:

4241881, 530350, 435 693

Abstract:

This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof. Also provided are antibodies generated against the modified polypeptides and trimeric complexes, and methods of using the modified polypeptides, compositions and trimeric complexes.